Who are Gentamicin + narrow spectrum betalactam's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gentamicin-narrow-spectrum-betalactam.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gentamicin + narrow spectrum betalactam — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gentamicin + narrow spectrum betalactam (Gentamicin + narrow spectrum betalactam) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside + Beta-lactam antibiotic combination. Area: Infectious Disease.

marketed Aminoglycoside + Beta-lactam antibiotic combination Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Gentamicin + narrow spectrum betalactam (Gentamicin + narrow spectrum betalactam) — University Hospital, Akershus. Gentamicin and a narrow-spectrum beta-lactam antibiotic work synergistically to kill bacteria by inhibiting protein synthesis and disrupting cell wall integrity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gentamicin + narrow spectrum betalactam TARGET	Gentamicin + narrow spectrum betalactam	University Hospital, Akershus	marketed	Aminoglycoside + Beta-lactam antibiotic combination	Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside + Beta-lactam antibiotic combination class)

University Hospital, Akershus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gentamicin + narrow spectrum betalactam — Competitive Intelligence Brief. https://druglandscape.com/ci/gentamicin-narrow-spectrum-betalactam. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab